Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2023 - 2025)

Historic Gains from Sales and Divestitures for Ocular Therapeutix (OCUL) over the last 4 years, with Q4 2025 value amounting to $1.6 million.

  • Ocular Therapeutix's Gains from Sales and Divestitures rose 2147.4% to $1.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year increase of 2147.4%. This contributed to the annual value of $1.6 million for FY2025, which is 2147.4% up from last year.
  • According to the latest figures from Q4 2025, Ocular Therapeutix's Gains from Sales and Divestitures is $1.6 million, which was up 2147.4% from $1.3 million recorded in Q4 2024.
  • Ocular Therapeutix's 5-year Gains from Sales and Divestitures high stood at $1.6 million for Q4 2025, and its period low was $393805.0 during Q4 2023.
  • Its 3-year average for Gains from Sales and Divestitures is $1.1 million, with a median of $1.3 million in 2024.
  • As far as peak fluctuations go, Ocular Therapeutix's Gains from Sales and Divestitures soared by 22437.32% in 2024, and later surged by 2147.4% in 2025.
  • Quarter analysis of 3 years shows Ocular Therapeutix's Gains from Sales and Divestitures stood at $393805.0 in 2023, then skyrocketed by 224.37% to $1.3 million in 2024, then rose by 21.47% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q4 2025, $1.3 million for Q4 2024, and $393805.0 during Q4 2023.